Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing.

4区 生物学 Q4 Biochemistry, Genetics and Molecular Biology
Methods in cell biology Pub Date : 2025-01-01 Epub Date: 2024-06-17 DOI:10.1016/bs.mcb.2024.05.013
Clara Diaz Garcia-Prada, Salima Atis, Jean-Pierre Pouget, Julie Constanzo
{"title":"Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing.","authors":"Clara Diaz Garcia-Prada, Salima Atis, Jean-Pierre Pouget, Julie Constanzo","doi":"10.1016/bs.mcb.2024.05.013","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, Ovarian Cancer (OC) is the most lethal gynecological malignancy. In most patients, it progresses without clinical signs or symptoms, leading to a late diagnosis when it has already spread in the peritoneal cavity as peritoneal carcinomatosis (PC). To date, OC PC management is based on cytoreductive surgery to remove the macroscopic disease, followed by chemotherapy. Many patients respond to this treatment, but disease recurs in 70-90% of them. Therefore, new therapeutic approaches are needed. The field of targeted radionuclide therapy (TRT) has witnessed considerable progress and several radiopharmaceuticals have been approved in the last decade. In TRT, radiolabeled molecules are injected to specifically recognize, irradiate, and kill tumor cells. TRT is a multisite radiotherapy that delivers dose to all malignant lesions. Therefore, TRT could be an alternative approach for OC PC because conventional external beam radiotherapy cannot be used at curative dose due to toxicity to healthy tissues. Here, we describe an OC PC model based on grafting human SK-OV-3 OC cells in the peritoneal cavity of immunodeficient mice. We also explain how to label trastuzumab with lutetium-177 to specifically target and irradiate SK-OV-3 cell nodules in these mice, and how to monitor the response to this TRT in vivo. With minor variations, the same technique can be conveniently applied to a variety of human (or mouse) tumors.</p>","PeriodicalId":18437,"journal":{"name":"Methods in cell biology","volume":"192 ","pages":"131-157"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methods in cell biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/bs.mcb.2024.05.013","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, Ovarian Cancer (OC) is the most lethal gynecological malignancy. In most patients, it progresses without clinical signs or symptoms, leading to a late diagnosis when it has already spread in the peritoneal cavity as peritoneal carcinomatosis (PC). To date, OC PC management is based on cytoreductive surgery to remove the macroscopic disease, followed by chemotherapy. Many patients respond to this treatment, but disease recurs in 70-90% of them. Therefore, new therapeutic approaches are needed. The field of targeted radionuclide therapy (TRT) has witnessed considerable progress and several radiopharmaceuticals have been approved in the last decade. In TRT, radiolabeled molecules are injected to specifically recognize, irradiate, and kill tumor cells. TRT is a multisite radiotherapy that delivers dose to all malignant lesions. Therefore, TRT could be an alternative approach for OC PC because conventional external beam radiotherapy cannot be used at curative dose due to toxicity to healthy tissues. Here, we describe an OC PC model based on grafting human SK-OV-3 OC cells in the peritoneal cavity of immunodeficient mice. We also explain how to label trastuzumab with lutetium-177 to specifically target and irradiate SK-OV-3 cell nodules in these mice, and how to monitor the response to this TRT in vivo. With minor variations, the same technique can be conveniently applied to a variety of human (or mouse) tumors.

用于放射免疫治疗试验的卵巢癌腹膜癌模型的建立。
目前,卵巢癌(OC)是最致命的妇科恶性肿瘤。在大多数患者中,它在没有临床体征或症状的情况下进展,导致当它已经扩散到腹膜腔时诊断为腹膜癌(PC)。迄今为止,卵巢癌的治疗是基于细胞减少手术切除宏观疾病,然后化疗。许多患者对这种治疗有反应,但其中70-90%的患者会复发。因此,需要新的治疗方法。靶向放射性核素治疗(TRT)领域在过去十年中取得了长足的进步,一些放射性药物已经获得批准。在TRT中,注射放射性标记分子特异性识别、照射和杀死肿瘤细胞。TRT是一种多部位放疗,可向所有恶性病灶提供剂量。因此,TRT可能是OC PC的替代方法,因为传统的外束放疗由于对健康组织的毒性而不能使用治疗剂量。在此,我们描述了一种基于移植人SK-OV-3 OC细胞于免疫缺陷小鼠腹腔的OC PC模型。我们还解释了如何用镥-177标记曲妥珠单抗来特异性靶向和照射这些小鼠中的SK-OV-3细胞结节,以及如何在体内监测对这种TRT的反应。通过微小的变化,同样的技术可以方便地应用于各种人类(或小鼠)肿瘤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Methods in cell biology
Methods in cell biology 生物-细胞生物学
CiteScore
3.10
自引率
0.00%
发文量
125
审稿时长
3 months
期刊介绍: For over fifty years, Methods in Cell Biology has helped researchers answer the question "What method should I use to study this cell biology problem?" Edited by leaders in the field, each thematic volume provides proven, state-of-art techniques, along with relevant historical background and theory, to aid researchers in efficient design and effective implementation of experimental methodologies. Over its many years of publication, Methods in Cell Biology has built up a deep library of biological methods to study model developmental organisms, organelles and cell systems, as well as comprehensive coverage of microscopy and other analytical approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信